Table 4.
Reduction of LDL‐C Over an Extended Follow‐up Period From First to Last Session of Apheresis
| Author | Country | Study Type | No. of FH Patients | Follow‐up Time | Mean LDL‐C Reduction Level (Range) mg/dL | Mean Percent LDL‐C Reduction |
|---|---|---|---|---|---|---|
| Archontakis 200727 | UK | Retrospective observational study | HeFH: 7 | 4 y 4 mo | 218.5 (159.7–323.3)a | 21.7% |
| Matsuzaki, 200240 | Japan | Open‐label clinical trial | HeFH: 19 | 1 y | 140 | 34.3% |
| Coker, 200925 | Turkey | Open‐label clinical trial | HoFH: 10 | 5 y | 238.8 | 36.4% |
| Hudgins, 200822 | USA | Prospective observational study | HoFH: 29 | Not reported | 341 | 34% |
| Blaha, 200944 | Czech Republic | Prospective observational study |
HoFH: 3 HeFH: 9 |
3 y | 201.1 | Not reported |
LDL‐C indicates low‐density lipoprotein cholesterol; FH indicates familial hypercholesterolemia; HeFH, heterozygous FH; HoFH, homozygous FH.
a
Conversion used, 1 mmol/L=38.66976 mg/dL.